Key result
Each 1 μmol/L decrease in serum α-ketoglutarate was independently associated with an 87% increased risk of all-cause death or CHD-related rehospitalization (HR 1.87) after interventional therapy.
Why the study?
The study was designed to explore the correlation between alpha-ketoglutarate and the oxidative stress response in patients with coronary heart disease and analyze the prognosis of patients undergoing interventional treatment.
Does serum α-ketoglutarate level predict all-cause death or CHD-related rehospitalization in patients with coronary heart disease undergoing interventional therapy?
Cohort (n=377)
No
Does serum α-ketoglutarate level predict all-cause death or CHD-related rehospitalization in patients with coronary heart disease undergoing interventional therapy?
Answers are grounded in this paper and cite their sources.
Lower serum α-ketoglutarate levels are independently associated with increased oxidative stress and a higher risk of adverse clinical events in patients with coronary heart disease undergoing interventional therapy.
Objective To explore the correlation between α-ketoglutarate and the oxidative stress response in patients with coronary heart disease (CHD) and to analyze the prognosis of CHD patients receiving interventional treatment. Methods A total of 318 CHD patients admitted from September 2020 to September 2023 were selected and divided into a conservative medical treatment group (159 patients) and an interventional treatment group (159 patients) according to the treatment plan. The interventional treatment group was divided into an event group and a nonevent group according to whether the primary endpoint event occurred; another 59 patients with healthy physical examination results during the same period composed the control group. The results The serum TAC, SOD, CAT, and GSH levels in the conservative medical treatment group were lower than those in the control group ( P < 0.05), and the serum MDA level was higher than that in the control group ( P < 0.05). α-Ketoglutarate was correlated with oxidative stress indicators (TAC, SOD, CAT, and GSH) in patients with CHD ( P < 0.05). A comparison of the α-ketoglutarate levels revealed that the control group > interventional treatment group > medical conservative treatment group ( P < 0.05) and that the α-ketoglutarate level in the event group was lower than that in the nonevent group ( P < 0.05). The ROC curve analysis results revealed that the area under the ROC curve (AUC) of α-ketoglutarate in the event group after interventional treatment was 702; the AUC of α-ketoglutarate in the no-event group was 802. Conclusion α-Ketoglutarate is related to oxidative stress in patients with CHD. The lower the serum α-ketoglutarate level is, the greater the likelihood that adverse events will occur.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2025) conducted a cohort in Coronary heart disease (n=377). Serum α-ketoglutarate vs. Higher serum α-ketoglutarate levels was evaluated on Primary endpoint events (all-cause death or CHD-related rehospitalization) (HR 1.87, 95% CI 1.29-2.71, p=0.001). Each 1 μmol/L decrease in serum α-ketoglutarate was independently associated with an 87% increased risk of all-cause death or CHD-related rehospitalization (HR 1.87) after interventional therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: